Tectonic Therapeutic Inc Stock Price, News & Analysis

Tectonic Therapeutic (NASDAQ: TECX) announced complete results from Part A of their Phase 1b clinical trial for TX45, their lead asset and long-acting relaxin therapy, in treating Group 2 Pulmonary Hypertension in Heart Failure patients. The trial, involving 19 patients, demonstrated significant positive outcomes: • Single intravenous dose was well-tolerated with no serious adverse events • Achieved 19.0% reduction in pulmonary capillary wedge pressure • Showed >30% reduction in Pulmonary Vascular Resistance in CpcPH patients • Demonstrated sustained hemodynamic improvements for 29 days • Improved cardiac output (18.5% increase) and pulmonary hemodynamics The data supports TX45's potential as a best-in-class therapy for Group 2 pulmonary hypertension, with particularly strong benefits for CpcPH patients. The company expects topline data from Part B of the Phase 1b study in HFrEF patients in H2 2025.

Tectonic Therapeutic (NASDAQ: TECX) reported its Q1 2025 financial results and business updates. The company highlighted positive interim results from its TX45 Phase 1b Part A trial for PH-HFpEF patients, showing a 17.9% reduction in PCWP and >30% reduction in PVR for severe cases. The company successfully completed a $185 million PIPE financing in February 2025, strengthening its cash position to $306.2 million as of March 31, 2025, extending runway into Q4 2028. Tectonic initiated Part B of the TX45 Phase 1b trial in March 2025, with topline results expected in H2 2025. The company reported a net loss of $15.9 million for Q1 2025, with R&D expenses of $13.0 million and G&A expenses of $5.3 million. Full results from the Phase 1b Part A trial will be presented at the ESC Heart Failure Congress on May 17, 2025, while the APEX Phase 2 trial continues with results expected in 2026.

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for GPCR modulation, has announced its participation in the Bank of America Securities 2025 Health Care Conference in Las Vegas. Dr. Alise Reicin, President and CEO, will deliver a corporate presentation on Thursday, May 15th, 2025, at 9:20am PDT.

The management team will be available for one-on-one meetings with investors during the conference. A live webcast will be accessible through the company's website, with a replay available for approximately 90 days after the event.

Tectonic Therapeutic (NASDAQ: TECX) has announced an upcoming late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress in Belgrade, Serbia. The presentation will showcase the complete Phase 1b results for TX45, the company's lead asset designed as a long-acting relaxin therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

The presentation, scheduled for May 17, 2025, will expand upon the interim data previously disclosed on January 30, 2025. Chief Development Officer Anthony Muslin, MD, will present the hemodynamic effects of TX45, which is being developed as a potential best-in-class therapy. The session will focus on late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension, and valvular heart disease.

Tectonic Therapeutic (NASDAQ: TECX) reported Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's TX45 Phase 1b trial showed promising interim results with a 17.9% reduction in Pulmonary Capillary Wedge Pressure in PH-HFpEF patients and over 30% reduction in Pulmonary Vascular Resistance in CpcPH patients.

Financial highlights include $141.2 million in cash and cash equivalents as of December 31, 2024, plus $185.0 million from a February 2025 private placement, extending cash runway into Q4'28. Q4 2024 saw increased R&D expenses of $9.2 million (vs $7.1M in Q4 2023) and net loss of $12.4 million (vs $7.9M in Q4 2023).

Key upcoming milestones include Phase 1b Part B results expected in 2H'25, APEX Phase 2 trial results in 2026, and TX2100 Phase 1 initiation for HHT treatment in Q4'25 or Q1'26.

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.

The company will provide live webcasts of both events, accessible through the 'Events & Presentations' section of their website at www.tectonictx.com. Recordings will remain available for approximately 90 days after the conferences conclude.

The management team will conduct one-on-one meetings with investors during both conferences. Interested parties are advised to contact their TD Cowen and/or Leerink representatives to arrange meetings.

Tectonic Therapeutic (NASDAQ: TECX) has secured a private investment in public equity (PIPE) financing of $185.0 million through the issuance of 3,689,465 shares of common stock. The shares will be priced at $50.00 per share for fund investors and $54.14 per share for company officers and directors.

The PIPE financing attracted both new and existing investors, including notable participants such as Adage Capital Partners LP, Ally Bridge Group, Deep Track Capital, and several other prominent investment firms. The proceeds will be used to fund the clinical development of TX45 and TX2100, discovery platform development, working capital, and general corporate purposes.

The transaction is expected to close on February 5, 2025, subject to customary closing conditions. TD Cowen, Leerink Partners, Piper Sandler, and Wells Fargo Securities served as placement agents for the PIPE.

Tectonic Therapeutic (NASDAQ: TECX) announced positive interim data from its Phase 1b trial of TX45, showing significant improvements in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The trial demonstrated a 17.9% reduction in Pulmonary Capillary Wedge Pressure in the total study population and over 30% reduction in Pulmonary Vascular Resistance in patients with more severe disease (CpcPH).

The interim analysis included 16 of 19 enrolled patients, with 9 having CpcPH. TX45 was well-tolerated with no serious adverse events. The drug showed improvement in both left ventricular function and pulmonary hemodynamics, demonstrating a unique therapeutic profile compared to other PAH drugs. The company's ongoing APEX Phase 2 trial is expected to deliver topline results in 2026.

Tectonic Therapeutic (NASDAQ: TECX) announces a virtual key opinion leader (KOL) event scheduled for December 12, 2024, from 4:00 PM to 6:00 PM ET. The event will feature experts Dr. John R. Teerlink from UC San Francisco and Dr. Raymond L. Benza from Icahn School of Medicine at Mount Sinai.

The discussion will focus on the unmet medical needs and current treatment landscape for Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF). The event will highlight Tectonic's lead program, TX45, an Fc-relaxin fusion protein that activates the RXFP1 receptor. TX45 is currently being evaluated in both Phase 1b hemodynamic and Phase 2 clinical proof-of-concept studies for Group 2 PH-HFpEF treatment.